U.S. Private Sector Sheds 32,000 Jobs in November, Sparking Market Shifts; Bristol Myers Squibb Advances Alzheimer’s Study

By / / Breaking News

This update was written automatically with AI from market data and news wire reports, and published without review by a person.

Key Takeaways

  • The U.S. private sector unexpectedly shed 32,000 jobs in November, significantly missing economist expectations for a 10,000 gain and reversing October's revised 47,000 increase, signaling a cooling labor market.
  • Following the weaker-than-anticipated ADP report, the U.S. Dollar Index extended its fall by 0.45% to 98.90, while 10-year Treasury yields dropped 3.4 basis points to 4.053%.
  • Spot gold prices saw a slight uptick, rising 0.3% to $4,220.72 per ounce, as investors reacted to the latest employment data.
  • Bristol Myers Squibb (BMY) announced the continuation of its ADEPT-2 Phase 3 study, evaluating a treatment for psychosis associated with Alzheimer's disease.

The U.S. labor market showed unexpected weakness in November, as the private sector experienced a net loss of 32,000 jobs. This figure sharply contrasted with the market's expectation of a 10,000 job gain and marked a significant deceleration from October's revised increase of 47,000 private payrolls. Despite the job losses, annual pay grew by 4.4%.

Financial markets reacted swiftly to the disappointing employment data. The U.S. Dollar Index extended its decline, falling 0.45% to 98.90. Concurrently, U.S. Treasury yields also moved lower, with the benchmark 10-year yield decreasing by 3.4 basis points to 4.053%. These movements suggest investor sentiment is shifting towards expectations of a less hawkish stance from the Federal Reserve, given the signs of a weakening economy.

In commodity markets, spot gold saw a modest increase of 0.3%, reaching $4,220.72 per ounce immediately after the ADP report's release. Gold often benefits from economic uncertainty and a weaker dollar, serving as a safe-haven asset.

In corporate news, pharmaceutical giant Bristol Myers Squibb (BMY) confirmed the continuation of its ADEPT-2 Phase 3 study. This critical clinical trial is investigating a potential treatment for psychosis associated with Alzheimer's disease, a significant area of unmet medical need.

Meanwhile, European Central Bank (ECB) President Christine Lagarde is scheduled to speak in the European Parliament around 13:30 GMT. Her remarks will be closely watched for any insights into the ECB's monetary policy outlook amidst evolving global economic conditions.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top